Higher perioperative dexamethasone exposure is associated with shorter survival in glioblastoma
Neuro-Oncology Advances · 12.01.2026 · 8 (1)
DOI: 10.1093/noajnl/vdag099 ↗Kurz gefasst
Fachartikel in der Zeitschrift Neuro-Oncology Advances, online erschienen am 13.04.2026. Verfasst von Severin Rüssli und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Swiss Academy of Medical Sciences through a Young Talents in Clinical Research.
Abstract (Originalsprache)
Background
Dexamethasone (DEX) is routinely administered perioperatively to manage tumor-associated vasogenic edema in glioblastoma (GBM), yet increasing evidence suggests that corticosteroid exposure may adversely affect survival. The magnitude of this association during the initial neurosurgical phase of care remains unclear.
Methods
We performed a retrospective cohort study of patients with histologically confirmed IDH-wildtype GBM treated at a single tertiary center between 2009 and 2020. All perioperative DEX doses from admission to discharge were extracted from daily medical records. Patients were stratified based on the cumulative dose into low-dose exposure (<34 mg) and high-dose exposure (≥34 mg) groups using maximally selected rank statistics. Overall survival was analyzed using Kaplan-Meier estimates with log-rank test and multivariable Cox proportional hazards models. Adjustment variables were selected using a prespecified, causally informed framework to address confounding.
Results
A total of 420 patients were included. The majority (n = 341; 81.2%) received ≥34 mg DEX perioperatively. Median OS was 13.6 months in the high-dose group and 15.0 months in the low-dose group, with significantly shorter survival observed in the high-dose cohort (log-rank P = .0103). In the adjusted Cox model, cumulative DEX ≥ 34 mg remained independently associated with increased mortality (HR: 1.40, 95% CI: 1.07-1.83; P = .013).
Conclusions
Higher perioperative DEX doses were independently associated with shorter overall survival in GBM patients, emphasizing the need for judicious perioperative use with prompt tapering. Prospective studies are warranted to guide evidence-based DEX management in GBM care.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Neurosurgery, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
- Department of Neurosurgery, LUKS, Cantonal Hospital of Lucerne, Lucerne, Switzerland.
- Department of Neurology, University Hospital Frankfurt, Goethe University, Frankfurt am Main, Germany.
- Institute of Tissue Medicine and Pathology, University of Bern, Bern, Switzerland.
ORCID-Profile: Severin Rüssli, Johannes Goldberg
Förderung
- Swiss Academy of Medical Sciences through a Young Talents in Clinical Research
Zitieren
APA
Rüssli, S., Descombes, C., Terrapon, A. P. R., Hinsberger, M., Maragkou, T., Zubak, I., Häni, L., Schucht, P., Raabe, A., & Goldberg, J. (2026). Higher perioperative dexamethasone exposure is associated with shorter survival in glioblastoma. Neuro-Oncology Advances, 8(1). https://doi.org/10.1093/noajnl/vdag099
Vancouver
Rüssli S, Descombes C, Terrapon APR, Hinsberger M, Maragkou T, Zubak I, et al. Higher perioperative dexamethasone exposure is associated with shorter survival in glioblastoma. Neuro-Oncology Advances. 2026;8(1). doi:10.1093/noajnl/vdag099
BibTeX
@article{Rssli2026,
author = {Rüssli, Severin and Descombes, Claire and Terrapon, Alexis P R and Hinsberger, Manuel and Maragkou, Theoni and Zubak, Irena and Häni, Levin and Schucht, Philippe and Raabe, Andreas and Goldberg, Johannes},
title = {Higher perioperative dexamethasone exposure is associated with shorter survival in glioblastoma},
journal = {Neuro-Oncology Advances},
year = {2026},
volume = {8},
number = {1},
doi = {10.1093/noajnl/vdag099}
}
EUVIMED